Gonadorelin vs Leuprolide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGonadorelinLeuprolide
What it is

A synthetic decapeptide identical to gonadotropin-releasing hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), according to FDA’s substance registry.9

A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.3

FDA status

FDA-approved

FDA-approved as Factrel and Lutrepulse; discontinued1,2

FDA-approved, but discontinued. Drugs@FDA lists Factrel, NDA 018123, approved September 30, 1982, and Lutrepulse, NDA 019687, approved October 10, 1989, and lists all of their products as discontinued.1,2

Is gonadorelin FDA-approved?

FDA-approved

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products3,4,5,6,7,8

FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.3,4,6

Is leuprolide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.10

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Gonadorelin is not among them.10,11

Not among the six peptides the policy lists.10

FDA compounding safety-risk page

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list gonadorelin.12

Not addressed in this profile’s sources.

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study A multicenter study of gonadorelin acetate (Lutrepulse) in 109 women with primary or secondary hypothalamic amenorrhea, in which 91% and 96% ovulated; 12% of pregnancies were multiple.13

Limited human data

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.3
Records collected

5 ClinicalTrials.gov records and 16 PubMed records collected

117 ClinicalTrials.gov records and 48 PubMed records collected

Area of study

Hormones, Sexual and reproductive health9,13

Sexual and reproductive health, Cancer

Latest dated events
  1. A multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea is published.13
  2. FDA approves Lutrepulse (gonadorelin acetate), NDA 019687, according to Drugs@FDA.2
  3. FDA approves Factrel (gonadorelin hydrochloride), NDA 018123, according to Drugs@FDA.1
  1. FDA approves Vobrig for central precocious puberty in children.7,8
  2. DailyMed publishes the Eligard label version cited on this page.3
  3. FDA approves Fensolvi, according to Drugs@FDA.14

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  9. 9
    Gonadorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  10. 10
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  11. 11
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  12. 12
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  13. 13
    Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection (1990) · PMID 2122733 ↗

    American Journal of Obstetrics and Gynecology · Official source · Source checked November 16, 2026

  14. 14
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026